[THE INVESTOR] Humedix, a subsidiary of Huons Global, said on April 16 that it has obtained sales approval for two types of injection therapies that repair damaged skin and encourage wound healing.
The products -- Revitalrex and Revitalrex prefilled syringe -- are based on Polydeoxyribonucleotide, or PDRN, which is extracted from salmon trout sperm and is being used for cell regeneration in various medical fields including dermatology.
“Revitalrex is a key product that will lead Humedix’s mid- to long-term growth. We plan to expand our portfolio to aesthetics sector including skin care and cosmetic medical devices as well as arthritis treatment,” said Humedix CEO Jung Gu-wan in a statement.
With the approval, Humedix is beefing up its pipeline mainly depended on hyaluronic acid injections for rheumatoid arthritis and dermal fillers.
By Park Han-na (firstname.lastname@example.org)